GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Other Income (Minority Interest)

Oxford BioMedica (LSE:OXB) Other Income (Minority Interest) : £26.67 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Oxford BioMedica's Other Income (Minority Interest) for the six months ended in Dec. 2023 was £21.97 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was £26.67 Mil.


Oxford BioMedica Other Income (Minority Interest) Historical Data

The historical data trend for Oxford BioMedica's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Other Income (Minority Interest) Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Minority Interest)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 6.00 26.67

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Income (Minority Interest) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.15 3.85 4.71 21.97

Oxford BioMedica Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £26.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica  (LSE:OXB) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Oxford BioMedica (LSE:OXB) Business Description

Industry
Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines